search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


De veiligheid van ciprofloxacine op het kraakbeen in de behandeling van kinderen met acute lymfatische leukemie (ALL).


- candidate number13342
- NTR NumberNTR3623
- ISRCTNISRCTN wordt niet meer aangevraagd.
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR20-sep-2012
- Secondary IDs41786 ABR
- Public TitleDe veiligheid van ciprofloxacine op het kraakbeen in de behandeling van kinderen met acute lymfatische leukemie (ALL).
- Scientific TitleSkeletal complications of prophylactic ciprofloxacin in the treatment of pediatric ALL.
- ACRONYMCipro MRI trial
- hypothesisTo determine the musculoskeletal safety of standard prophylactic treatment with ciprofloxacin and co-administered glucocorticoids in pediatric patients with acute lymphoblastic leukemia (ALL).
- Healt Condition(s) or Problem(s) studiedSafety, Acute Lymfatic Leukemia (ALL), Children, Ciprofloxacin, Cartilage damage
- Inclusion criteria1. >= 8 to <19 years;
2. Diagnosed with acute lymphoblastic leukemia;
3. Treated according to DCOG ALL-11 protocol;
4. Patients who will receive ciprofloxacin as antimicrobial prophylaxis as defined in the DCOG ALL-11 protocol (15 mg/kg/dose BID).
- Exclusion criteria1. Patients needing general anesthesia to undergo MRI;
2. Children with Down syndrome or other underlying syndromes;
3. Patients unable to undergo MRI due to claustrophobia;
4. Patients with underlying skeletal disorders, including prior fractures of the knees;
5. Patients with (juvenile rheumatoid) arthritis;
6. Patients with metallic implants and foreign bodies in and around the knee joint (although they may be MRI compatible; image artefacts).
- mec approval receivedyes
- multicenter trialno
- randomisedno
- groupParallel
- TypeSingle arm
- Studytypeobservational
- planned startdate 1-dec-2012
- planned closingdate1-dec-2017
- Target number of participants62
- Interventions2-3 MRIs will be taken of both knees. If cartilage damage is observed, the patient will undergo 1 or 2 additional MRIs.
- Primary outcomeThe main study endpoint is cartilage damage as determined by MRI, compared to a baseline MRI. The amount of important structural components of cartilage (e.g. collagen and glycosaminoglycans) will be measured and mapped quantitatively, for a sensitive and objective quantitative outcome measure of cartilage quality.
- Secondary outcomeClinical complaints concerning musculoskeletal system scored according to CTCAE grading system.
- Timepoints1. Baseline MRI: Within first week of diagnosis of ALL;
2. Second MRI: After 8 weeks (1 wk) of ciprofloxacin exposure;
3. In medium risk and high risk (ALL-11 protocol grading): Within 2 weeks after discontinuation of ciprofloxacin treatment;
4. If cartilage damage is present: 1 MRI yearly up to one year after discontinuation ALL treatment.
- Trial web siteN/A
- statusplanned
- CONTACT FOR PUBLIC QUERIES S.D.T. Sassen
- CONTACT for SCIENTIFIC QUERIESMD, PhD C.M. Zwaan
- Sponsor/Initiator Erasmus Medical Center
- Funding
(Source(s) of Monetary or Material Support)
Kinderen Kankervrij (KiKa), Go4Children
- PublicationsN/A
- Brief summaryCiprofloxacin has been associated with skeletal safety concerns and is therefore formally contra-indicated (with some exceptions) in patients <18 years of age. During the treatment of ALL, patients receive ciprofloxacin for microbiological prophylaxis. Currently, therapeutic doses of ciprofloxacin are used for prophylaxis due to a lack of information on optimal dosing in the prophylactic setting. The drug is given for prolonged periods of time due to recurrent neutropenia and increased risk of infections. However the musculoskeletal safety of ciprofloxacin has not been studied in this setting. Irreversible cartilage toxicity has been observed in animal studies, especially in weight baring joints. The incidence of reported clinical complains of the musculoskeletal system in children treated with quinolones varies between 0-23%. In addition, patients are simultaneously treated with glucocorticoids, which are known to induce osteonecrosis and osteopenia. Hence this combination might result in synergistic skeletal toxicity in these patients.
- Main changes (audit trail)
- RECORD20-sep-2012 - 12-jul-2013


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl